Lilly’s Donanemab Could Be A Near-Term Aduhelm Competitor

Company Will File For Accelerated Approval

 
• By Mandy Jackson
  
Amyloid plaques forming between neurons
The amyloid plaque surrogate endpoint behind Aduhelm's accelerated approval could benefit donanemab and other drugs • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category